Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Fluctuation of systemic immunity in melanoma and implications for timing of therapy.

Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN.

Front Biosci (Elite Ed). 2012 Jan 1;4:958-75.


Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.

Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B, Baudin M, Escudier B, Heinzerling L, Morant R, Herrmann R, Dietrich PY, Dummer R.

Cancer Gene Ther. 2002 Mar;9(3):289-95.


Personalized therapy for metastatic melanoma: could timing be everything?

Dronca RS, Leontovich AA, Nevala WK, Markovic SN.

Future Oncol. 2012 Nov;8(11):1401-6. doi: 10.2217/fon.12.126. Review.


Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.

Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, Rao RD, Creagan ET, Pittelkow MR, Allred JB, Nevala WK, Celis E.

Am J Clin Oncol. 2006 Aug;29(4):352-60.


Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.

Ridolfi L, Ridolfi R.

Hepatogastroenterology. 2002 Mar-Apr;49(44):335-9.


Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.

Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA.

Cancer. 2008 Oct 15;113(8):2139-45. doi: 10.1002/cncr.23805.


Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.

Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA.

J Transl Med. 2009 Jul 29;7:68. doi: 10.1186/1479-5876-7-68.


Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.

Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S.

Clin Cancer Res. 2011 Jul 1;17(13):4568-80. doi: 10.1158/1078-0432.CCR-11-0184.


Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.

Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman WH.

J Clin Oncol. 1996 May;14(5):1697-703.


Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.

Redman BG, Flaherty L, Chou TH, Nakeff A, Pillote K, Kaplan J.

J Immunother (1991). 1991 Apr;10(2):147-51.


Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.

Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E.

Clin Cancer Res. 1996 Jan;2(1):29-36.


Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.

O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW.

Cancer Immunol Immunother. 2003 Jun;52(6):387-95.


A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.

Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchian├▓ A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G.

Cancer Immunol Immunother. 2006 Aug;55(8):958-68.


Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma.

Hollinshead A, Arlen M, Yonemoto R, Cohen M, Tanner K, Kundin WD, Scherrer J.

Cancer. 1982 Apr 1;49(7):1387-404.


Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

de Gast GC, Kl├╝mpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.

Clin Cancer Res. 2000 Apr;6(4):1267-72.


Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.

Isacson R, Kedar E, Barak V, Gazit Z, Yurim O, Kalichman I, Ben-Bassat H, Biran S, Schlesinger M, Franks CR, et al.

Immunol Lett. 1992 Jul;33(2):127-34.


Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.

Vaishampayan U, Abrams J, Darrah D, Jones V, Mitchell MS.

Clin Cancer Res. 2002 Dec;8(12):3696-701. Review.


The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.

Tsavaris N, Baxevanis C, Kosmidis P, Papamichael M.

Cancer Immunol Immunother. 1996 Oct;43(2):94-102.

Items per page

Supplemental Content

Support Center